产后轻度高血压的严格与宽松控制:一项随机对照试验
这项实用主义多中心随机对照试验纳入256例产后高血压患者,比较以140/90 mm Hg(严格组)与150/95 mm Hg(宽松组)为启动降压治疗阈值的差异。主要复合母体并发症发生率两组相似(8.6% vs 11.7%;P=.41;相对风险0.73;95%CI 0.35-1.53),所有次要结局亦相似。结论认为较低阈值启动降压未降低母体并发症或改善结局。
要点
- 产后以140/90 mm Hg为阈值启动降压治疗,主要复合母体并发症与150/95 mm Hg阈值无显著差异。
- 严格组主要结局8.6% vs 宽松组11.7%(P=.41;相对风险0.73;95%CI 0.35-1.53)。
- 所有次要结局及主要和次要结局的单项组分两组均相似。
核心结论
- 产后以140/90 mm Hg较低阈值启动降压治疗,与150/95 mm Hg阈值相比,未降低母体并发症或改善结局。
研究设计与样本
- 实用主义多中心随机对照试验,纳入18至55岁产后高血压患者,包括慢性高血压、妊娠期高血压及无严重特征子痫前期。
- 共随机256例,严格组(≥140/90 mm Hg启动治疗)128例,宽松组(≥150/95 mm Hg启动治疗,机构标准)128例。
- 主要结局为复合母体并发症:严重高血压(血压≥160/110 mm Hg)或子痫前期伴严重特征、需第二种降压药、产后住院>4天、高血压继发母体不良结局(肺水肿、急性肾损伤肌酐≥1.1 mg/dL、心脏功能障碍如脑钠肽升高或心肌病、可逆性后部脑病综合征、脑血管意外或入住重症监护室)。
- 样本量计算:256例提供90%把握度检测主要结局从标准阈值组36%至18%的相对50%降低,双侧α=0.05。
- 数据使用R统计软件分析。
主要发现
- 严格组分娩时体重指数高于宽松组(37.1±9.4 vs 34.9±8.1;P=.04),其他人口学和产科特征两组相似。
- 主要结局发生率两组相似(8.6% vs 11.7%;P=.41;相对风险0.73;95%CI 0.35-1.53)。
- 所有次要结局及主要和次要结局的单项组分发生率两组亦相似。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-quality evidence to inform the management of postpartum hypertension, including the optimal blood pressure threshold to initiate therapy, is lacking. Randomized trials have been conducted in pregnancy, but there are no published trials to guide management in the postpartum period. OBJECTIVE: This study aimed to test the hypothesis that initiating antihypertensive therapy in the postpartum period at a threshold of 140/90 mm Hg would result in less maternal morbidity than initiating therapy at a threshold of 150/95 mm Hg. STUDY DESIGN: We performed a pragmatic multicenter randomized controlled trial of patients aged 18 to 55 years with postpartum hypertension. Patients with chronic hypertension, gestational hypertension, and preeclampsia without severe features were randomized to 1 of 2 blood pressure thresholds to initiate treatment: persistent blood pressure of ≥150/95 mm Hg (institutional standard or "liberal control" group) or ≥140/90 mm Hg (intervention or "tight control" group). Our primary outcome was composite maternal morbidity defined as: severe hypertension (blood pressure ≥160/110 mm Hg) or preeclampsia with severe features, the need for a second antihypertensive agent, postpartum hospitalization >4 days, and maternal adverse outcome secondary to hypertension as evidenced by pulmonary edema, acute kidney injury (creatinine level ≥1.1 mg/dL), cardiac dysfunction (eg, elevated brain natriuretic peptide level) or cardiomyopathy, posterior reversible encephalopathy syndrome, cerebrovascular accident, or admission to an intensive care unit. Secondary outcomes included hospital readmission for hypertension, persistence of hypertension beyond 14 days, medication side effects, and time to blood pressure control. We calculated that 256 women would provide 90% power to detect a relative 50% reduction in the primary outcome from 36% in the standard blood pressure threshold group to 18%, with a 2-sided alpha set at 0.05 for significance. Data were analyzed using R statistical software. RESULTS: A total of 256 patients were randomized, including 128 to the "tight control" group (140/90 mm Hg) and 128 to the "liberal control" group (150/95 mm Hg). Patients in the "tight control" group had a higher body mass index at delivery (37.1±9.4 vs 34.9±8.1; P=.04); other demographic and obstetrical characteristics were similar between groups. The rate of the primary outcome was similar between groups (8.6% vs 11.7%; P=.41; relative risk, 0.73; 95% confidence interval, 0.35-1.53). The rates of all secondary outcomes and the individual components of the primary and secondary outcome measures were also similar between groups. CONCLUSION: In the postpartum period, initiation of antihypertensive therapy at a lower blood pressure threshold of 140/90 mm Hg did not decrease maternal morbidity or improve outcomes compared with a threshold of 150/95 mm Hg.
引用
- Aderibigbe OA, Hackney DN, Ranzini AC, et al. Tight vs liberal control of mild postpartum hypertension: a randomized controlled trial. Am J Obstet Gynecol MFM. 2022. PMID: 36402355. doi:10.1016/j.ajogmf.2022.100818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。